{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:43:45Z","timestamp":1790808225092,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"39","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"name":"American Heart Association Strategically Focused Research Network in Vascular Disease","award":["18SFRN3390085"],"award-info":[{"award-number":["18SFRN3390085"]}]},{"name":"American Heart Association Strategically Focused Research Network in Vascular Disease","award":["18SFRN33960262"],"award-info":[{"award-number":["18SFRN33960262"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>In this secondary analysis of the VOYAGER trial, rivaroxaban 2.5 mg twice\/day plus aspirin 100 mg\/day was assessed in older adults. Advanced age is associated with elevated bleeding risk and unfavourable net benefit for dual antiplatelet therapy in chronic coronary artery disease. The risk\u2013benefit of low-dose rivaroxaban in patients \u226575 years with peripheral artery disease (PAD) after lower extremity revascularization (LER) has not been described.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>The primary endpoint was a composite of acute limb ischaemia, major amputation, myocardial infarction, ischaemic stroke, or cardiovascular death. The principal safety outcome was thrombolysis in myocardial infarction (TIMI) major bleeding analysed by the pre-specified age cut-off of 75 years. Of 6564 patients randomized, 1330 (20%) were &amp;gt;75 years. Absolute 3-year Kaplan\u2013Meier cumulative incidence rates for primary efficacy (23.4% vs. 19.0%) and safety (3.5% vs. 1.5%) endpoints were higher in elderly vs. non-elderly patients. Efficacy of rivaroxaban (P-interaction 0.83) and safety (P-interaction 0.38) was consistent irrespective of age. The combination of intracranial and fatal bleeding was not increased in patients &amp;gt;75 years (2 rivaroxaban vs. 8 placebo). Overall, benefits (absolute risk reduction 3.8%, number needed to treat 26 for the primary endpoint) exceeded risks (absolute risk increase 0.81%, number needed to harm 123 for TIMI major bleeding).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients \u226575 years with PAD are at both heightened ischaemic and bleeding risk after LER. No excess harm with respect to major, intracranial or fatal bleeding was seen in older patients yet numerically greater absolute benefits were observed. This suggests that low-dose rivaroxaban combined with aspirin should be considered in PAD after LER regardless of age.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehab408","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T11:12:28Z","timestamp":1623841948000},"page":"4040-4048","source":"Crossref","is-referenced-by-count":23,"title":["Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial"],"prefix":"10.1093","volume":"42","author":[{"given":"Mori J","family":"Krantz","sequence":"first","affiliation":[{"name":"CPC Clinical Research , 2115 N Scranton Street, Suite 2040, Aurora, CO, USA"},{"name":"Department of Medicine, University of Colorado School of Medicine , Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-8644","authenticated-orcid":false,"given":"Sebastian E","family":"Debus","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Vascular Surgery\u2013Angiology\u2013Endovascular Therapy, University of Hamburg-Eppendorf , Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3413-7836","authenticated-orcid":false,"given":"Judith","family":"Hsia","sequence":"additional","affiliation":[{"name":"CPC Clinical Research , 2115 N Scranton Street, Suite 2040, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manesh R","family":"Patel","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Division of Cardiology, Duke University , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia S","family":"Anand","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, Hamilton Health Sciences and McMaster University , Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1012-7307","authenticated-orcid":false,"given":"Mark R","family":"Nehler","sequence":"additional","affiliation":[{"name":"CPC Clinical Research , 2115 N Scranton Street, Suite 2040, Aurora, CO, USA"},{"name":"Department of Surgery, Division of Vascular Surgery, University of Colorado School of Medicine , Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-0511","authenticated-orcid":false,"given":"Connie N","family":"Hess","sequence":"additional","affiliation":[{"name":"CPC Clinical Research , 2115 N Scranton Street, Suite 2040, Aurora, CO, USA"},{"name":"Department of Medicine, University of Colorado School of Medicine , Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1073-3721","authenticated-orcid":false,"given":"Warren H","family":"Capell","sequence":"additional","affiliation":[{"name":"CPC Clinical Research , 2115 N Scranton Street, Suite 2040, Aurora, CO, USA"},{"name":"Department of Medicine, University of Colorado School of Medicine , Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Bracken","sequence":"additional","affiliation":[{"name":"CPC Clinical Research , 2115 N Scranton Street, Suite 2040, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-0264","authenticated-orcid":false,"given":"Michael","family":"Szarek","sequence":"additional","affiliation":[{"name":"CPC Clinical Research , 2115 N Scranton Street, Suite 2040, Aurora, CO, USA"},{"name":"SUNY Downstate Health Sciences University , 450 Clarkson Ave, Brooklyn, NY 11203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"M\u00e1ty\u00e1s","sequence":"additional","affiliation":[{"name":"Borsod Central Teaching County Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dainis K","family":"Krievins","sequence":"additional","affiliation":[{"name":"University of Latvia , Latvia"},{"name":"Pauls Stradins Clinical University Hospital, Vascular and Endovascular Surgery CISSSO , Gatineau, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8202-5401","authenticated-orcid":false,"given":"Patrice","family":"Nault","sequence":"additional","affiliation":[{"name":"McGill University , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Stefanov","sequence":"additional","affiliation":[{"name":"City Clinic Cardiology Centre Multiprofile Hospital for Active Treatment EOOD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd P","family":"Haskell","sequence":"additional","affiliation":[{"name":"Janssen Research and Development , Raritan, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9428-4408","authenticated-orcid":false,"given":"Scott D","family":"Berkowitz","sequence":"additional","affiliation":[{"name":"Thrombosis & Vascular Medicine, Clinical Development , Bayer U.S, Whippany, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Muehlhofer","sequence":"additional","affiliation":[{"name":"Bayer AG Research & Development, Pharmaceuticals , Wuppertal, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R","family":"Hiatt","sequence":"additional","affiliation":[{"name":"CPC Clinical Research , 2115 N Scranton Street, Suite 2040, Aurora, CO, USA"},{"name":"Department of Medicine, University of Colorado School of Medicine , Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-1741","authenticated-orcid":false,"given":"Rupert M","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Klinikum Darmstadt, Darmstadt , Germany"},{"name":"Center for Thrombosis and Hemostasis, University of Mainz , Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-3584","authenticated-orcid":false,"given":"Marc P","family":"Bonaca","sequence":"additional","affiliation":[{"name":"CPC Clinical Research , 2115 N Scranton Street, Suite 2040, Aurora, CO, USA"},{"name":"Department of Medicine, University of Colorado School of Medicine , Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"2022102514464822400_ehab408-B1","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1161\/01.CIR.0000137913.26087.F0","article-title":"Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000","volume":"110","author":"Selvin","year":"2004","journal-title":"Circulation"},{"key":"2022102514464822400_ehab408-B2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ahj.2014.06.013","article-title":"The impact of prolonged lower limb ischemia on amputation, mortality, and functional status: the FRIENDS registry","volume":"168","author":"Duval","year":"2014","journal-title":"Am Heart J"},{"key":"2022102514464822400_ehab408-B3","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"Steg","year":"2007","journal-title":"JAMA"},{"key":"2022102514464822400_ehab408-B4","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2017.02.064","article-title":"Underuse of prevention and lifestyle counseling in patients with peripheral artery disease","volume":"69","author":"Berger","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022102514464822400_ehab408-B5","first-page":"e686","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"key":"2022102514464822400_ehab408-B6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1161\/CIRCOUTCOMES.111.000072","article-title":"Perceived risk of ischemic and bleeding events in acute coronary syndromes","volume":"6","author":"Chew","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2022102514464822400_ehab408-B7","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.mayocp.2018.08.043","article-title":"Perception of the risk of stroke and the risks and benefits of oral anticoagulation for stroke prevention in patients with atrial fibrillation: a cross-sectional study","volume":"94","author":"Hijazi","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2022102514464822400_ehab408-B8","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cjca.2015.09.023","article-title":"Values and preferences of physicians and patients with nonvalvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention","volume":"32","author":"Andrade","year":"2016","journal-title":"Can J Cardiol"},{"key":"2022102514464822400_ehab408-B9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1445-5994.2002.00156.x","article-title":"Doctors' beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention","volume":"32","author":"Peterson","year":"2002","journal-title":"Intern Med J"},{"key":"2022102514464822400_ehab408-B10","doi-asserted-by":"crossref","first-page":"e006837","DOI":"10.1161\/CIRCINTERVENTIONS.118.006837","article-title":"Performance of PRECISE-DAPT score for predicting bleeding complication during dual antiplatelet therapy","volume":"11","author":"Choi","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"2022102514464822400_ehab408-B11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"2022102514464822400_ehab408-B12","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102514464822400_ehab408-B13","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102514464822400_ehab408-B14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2018.01.011","article-title":"Rationale and design for the vascular outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)","volume":"199","author":"Capell","year":"2018","journal-title":"Am Heart J"},{"key":"2022102514464822400_ehab408-B15","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jacc.2019.11.057","article-title":"Sex-specific risks of major cardiovascular and limb events in patients with symptomatic peripheral artery disease","volume":"75","author":"Haine","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102514464822400_ehab408-B16","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1001\/jama.292.17.2115","article-title":"Hospitalization, restricted activity, and the development of disability among older persons","volume":"292","author":"Gill","year":"2004","journal-title":"JAMA"},{"key":"2022102514464822400_ehab408-B17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/1358863X19826681","article-title":"Vorapaxar for secondary prevention in the elderly with peripheral artery disease: insights from the TRA 2P-TIMI 50 Trial","volume":"24","author":"Patel","year":"2019","journal-title":"Vasc Med"},{"key":"2022102514464822400_ehab408-B18","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102514464822400_ehab408-B19","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.ahj.2004.09.015","article-title":"The American Heart Association get with the guidelines program","volume":"148","author":"Smaha","year":"2004","journal-title":"Am Heart J"},{"key":"2022102514464822400_ehab408-B20","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","article-title":"Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial","volume":"71","author":"Anand","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102514464822400_ehab408-B21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacc.2019.11.050","article-title":"Long-term outcomes and associations with major adverse limb events after peripheral artery revascularization","volume":"75","author":"Hess","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102514464822400_ehab408-B22","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2017.03.024","article-title":"The treatment gap in peripheral artery disease","volume":"69","author":"Hiatt","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022102514464822400_ehab408-B23","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1161\/CIRCULATIONAHA.117.024469","article-title":"A structured review of antithrombotic therapy in peripheral artery disease with a focus on revascularization: a TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) initiative","volume":"135","author":"Hess","year":"2017","journal-title":"Circulation"},{"key":"2022102514464822400_ehab408-B24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ahj.2011.04.006","article-title":"Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials","volume":"162","author":"Berger","year":"2011","journal-title":"Am Heart J"},{"key":"2022102514464822400_ehab408-B25","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"2022102514464822400_ehab408-B26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamainternmed.2014.5802","article-title":"Secondary prevention of cardiovascular disease with vorapaxar: a new era of 3-drug antiplatelet therapy?","volume":"175","author":"Krantz","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2022102514464822400_ehab408-B27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"2022102514464822400_ehab408-B28","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1161\/CIRCULATIONAHA.120.047994","article-title":"Temporal changes in secondary prevention and cardiovascular outcomes after revascularization for peripheral arterial disease in Denmark: a nationwide cohort study","volume":"143","author":"S\u00f8gaard","year":"2021","journal-title":"Circulation"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/39\/4040\/46627063\/ehab408.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/39\/4040\/46627063\/ehab408.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T17:27:42Z","timestamp":1666718862000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/39\/4040\/6357238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":28,"journal-issue":{"issue":"39","published-online":{"date-parts":[[2021,8,25]]},"published-print":{"date-parts":[[2021,10,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab408","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,14]]},"published":{"date-parts":[[2021,8,25]]}}}